leveraxo 60mg modified-release tablets
viatris uk healthcare ltd - oxycodone hydrochloride - modified-release tablet - 60mg
leveraxo 80mg modified-release tablets
viatris uk healthcare ltd - oxycodone hydrochloride - modified-release tablet - 80mg
desferal 0.5 g.
novartis israel ltd - deferoxamine mesylate - powder for solution for inj/inf - deferoxamine mesylate 0.5 g/vial - deferoxamine - deferoxamine - treatment of chronic iron overload e.g.: transfusional haemosiderosis especially in thalassaemia major sideroblastic anaemia autoimmune haemolytic anaemia and other chronic anaemias idiopathic (primary) haemochromatosis in patients in whom concomitant disorders ( e.g. severe anaemia cardiac disease hypoproteinaemia) preclude phlebotomy iron overload associated with porphyria cutanea tarda. treatment of acute iron poisoning. treatment of chronic aluminium overload in patients with terminal renal failure (under maintenance dialysis) with: aluminium-related bone disease and/or dialysis encephalopathy and/or aluminium-related anaemia. diagnosis of iron overload.
desferal 500 milligram pdr/conc/soln/inj/inf
novartis pharmaceuticals uk ltd - deferoxamine mesilate - pdr/conc/soln/inj/inf - 500 milligram - iron chelating agents
vpriv
takeda new zealand limited - velaglucerase alfa 400 u; - powder for infusion concentrate - 400 u - active: velaglucerase alfa 400 u excipient: citric acid monohydrate polysorbate 20 sodium citrate dihydrate sucrose - vpriv is indicated for long-term enzyme replacement therapy (ert) for paediatric and adult patients with type i gaucher disease.
vpriv 400units powder for solution for infusion vials
shire pharmaceuticals ltd - velaglucerase alfa - powder for solution for infusion - 400unit
desferal 500mg powder for solution for injection
novartis ireland limited vista building, elm park, merrion road, ballsbridge, dublin 4,, ireland - deferoxamine - powder for solution for injection - deferoxamine 500 mg - all other therapeutic products
desferal 500mg vials powder for solution for injection or powder for concentrate for solution for infusion
novartis ireland limited - deferoxamine mesilate - powder for solution for injection/infusion - 500 milligram(s) - iron chelating agents; deferoxamine
desferal 0.5 g.
novartis israel ltd - deferoxamine mesylate - powder for solution for inj/inf - deferoxamine mesylate 0.5 g/vial - deferoxamine - treatment of chronic iron overload e.g.: transfusional haemosiderosis especially in thalassaemia major sideroblastic anaemia autoimmune haemolytic anaemia and other chronic anaemias idiopathic (primary) haemochromatosis in patients in whom concomitant disorders ( e.g. severe anaemia cardiac disease hypoproteinaemia) preclude phlebotomy iron overload associated with porphyria cutanea tarda. treatment of acute iron poisoning. treatment of chronic aluminium overload in patients with terminal renal failure (under maintenance dialysis) with: aluminium-related bone disease and/or dialysis encephalopathy and/or aluminium-related anaemia. diagnosis of iron overload.
desferal 0.5 g.
novartis israel ltd - deferoxamine mesylate - powder for solution for inj/inf - deferoxamine mesylate 0.5 g/vial - deferoxamine - treatment of chronic iron overload e.g.: transfusional haemosiderosis especially in thalassaemia major sideroblastic anaemia autoimmune haemolytic anaemia and other chronic anaemias idiopathic (primary) haemochromatosis in patients in whom concomitant disorders ( e.g. severe anaemia cardiac disease hypoproteinaemia) preclude phlebotomy iron overload associated with porphyria cutanea tarda. treatment of acute iron poisoning. treatment of chronic aluminium overload in patients with terminal renal failure (under maintenance dialysis) with: aluminium-related bone disease and/or dialysis encephalopathy and/or aluminium-related anaemia. diagnosis of iron overload.